Other

Japan Science and Technology Agency

Idemitsu Kosan Company, Limited

Mitsubishi Chemical Corporation

The University of Tokyo

Astellas Pharma Gmbh

Mitsubishi Kasei Corporation

Kishimoto Sangyo Co., Ltd.

Towa Pharmaceutical Co., Ltd.

Eiichi Nakamura

Yutaka Matsuo

Hitoshi Uchida

Masaya Sawamura

Saburo Koyama

Hiroyuki Isobe

Katsuhiko Kanaizuka

Laurean Ilies

Yoji Oderaotoshi

Takuhiro Izumi

Shigenobu Nishiguchi

Hiroshi Kato

Yasuhiro Morinaka

Yoshiharu Sato

Kyoko Nozaki

Hideo Kanamori

Yutaka Majima

Ryoichi Ando

Yoshihiro Murakami

Shintaro Nishimura

Keiko Matsuo

Masaharu Nakamura

Akihiko Iwashita

Takaaki Niinomi

Takashi Inoue

Hiroshi Maruyama

Masahiko Hashiguchi

Hideki Yorimitsu

Ryo Shintani

Kenichi Shibayama

Hayato Tsuji

Chun Ouyang

Yu-Wu Zhong

Ayako Muramatsu

Yuma Ito

Takahiro Nakae

SeungJoo Lee

Shingo Ito

A monomolecular transistor including a first electrode including a first electrode layer and a first metal particle arranged at one end of the first electrode layer, a second electrode including a first electrode layer and a first metal particle arranged at one end of the first electrode layer, a third electrode insulated from the first electrode and the second electrode, a &#x3c0;-conjugated molecule having a &#x3c0;-conjugated skeleton. The first metal particle and the second metal particle face each other. The third electrode is arranged adjacent to the gap in which the first metal particle and the second metal particle face each other, and is spaced from the first metal particle and the second metal particle, the &#x3c0;-conjugated molecule is arranged in a gap between the first metal particle and the second metal particle.

Monomolecular transistor

A highly pure optically active proton pump inhibitor compound can be produced safely and inexpensively in a high yield and enantioselectivity by a method of producing an optically active sulfoxide of Formula 2 or a salt thereof, comprising oxidizing a sulfide of Formula 1 or a salt thereof with hydrogen peroxide using an iron salt in the presence of a chiral ligand of Formula 3; wherein A is CH or N; Ris hydrogen atom, an alkyl optionally substituted by halogen(s), or an alkoxy optionally substituted by halogen(s); one to three Rmay exist, and each of Ris independently an alkyl, a dialkylamino, or an alkoxy optionally substituted by halogen(s) or alkoxy(s); each of Ris independently hydrogen atom, a halogen, cyano or the like; Ris a tertiary alkyl; and * and ** represent respectively R configuration or S configuration. 

Method of producing proton pump inhibitor compound having optical activity

Method for producing proton pump inhibitor compound having optical activity

The present invention provides a photoelectric conversion material comprising a fullerene derivative represented by the formula C(R)(R), wherein each Rindependently represents an organic group having a substituent; and Rrepresents a hydrogen atom or a substituted or unsubstituted C-Chydrocarbon group. Further, the present invention also provides a photoelectric conversion device having a self-assembled monomolecular film of the photoelectric conversion material, and a solar cell having the photoelectric conversion device.

Photoelectric conversion material containing fullerene derivative

The present invention provides a photoelectric conversion device having at least a fullerene derivative as an electron acceptor and a compound as an electron donor between a pair of electrodes, wherein the fullerene derivative has 2 to 4 organic groups which each independently have 1 to 50 carbon atoms, and wherein when the fullerene derivative has two organic groups, these organic groups do not bind to each other to form a ring.

Photoelectric converter and solar cell using the same

The present invention provides a photoelectric conversion material comprising a fullerene derivative represented by the formula C(R)(MLn), wherein: each Rindependently represents an organic group having a substituent; M represents a metal atom; L is a ligand of M; and n is the number of Ls. Further, the present invention also provides a photoelectric conversion device having a self-assembled monomolecular film of the photoelectric conversion material, and a solar cell having the photoelectric conversion device.

The present invention provides a fullerene derivative represented by the following formula (1): wherein in formula (1), Ris a substituted or unsubstituted organic group or a hydrogen atom, and wherein in formulae (2) and (3): W is a single bond, C-C, alkylene, C-Calkenylene, or C-Calkynylene, wherein any &#x2014;CH&#x2014; in the alkylene, alkenylene or alkynylene can be substituted with &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;COO&#x2014;, or &#x2014;OCO&#x2014;; Z is an element belonging to group IVB; and Rto Rare each independently a substituted or unsubstituted C-Calkyl group, a substituted or unsubstituted C-Calkenyl group, or a substituted or unsubstituted C-Calkynyl group.

Fullerene derivatives

The present invention provides a method for producing a fullerene derivative, comprising the organic group addition step B in which an organic group is further added by reacting at least a basic compound and a halogen compound with a fullerene derivative, which is obtained by addition of a hydrogen atom and an organic group in the organic group addition step A, in which an organic group is added by reacting at least a Grignard reagent and a polar substance with a fullerene or fullerene derivative.

Process for producing fullerene derivative

This invention relates to novelO-labeled monosaccharide useful for positron emission tomography (PET) and producing method thereof.

[object Object]

The present invention provides a method for producing a fullerene derivative comprising reacting: a fullerene; an organometallic reagent (A) comprising B, Al, Zn, Sn, Pb, Te, Ti, Mn, Zr or Sm; and a copper compound (B).

Fullerene derivative and methods for producing same

A problem of the present invention is to provide an economical process with minimized toxicity for producing an aromatic compound having a variety of substituents such as various alkyl groups, and the problem is solved by a process for production of an aromatic compound represented by formula (1) below, which comprises reacting a compound represented by formula (2) below with an aromatic magnesium reagent represented by formula (3a) below in the presence of an iron catalyst and a diamine compound: wherein R is an optionally substituted hydrocarbon group or a C-Csaturated or unsaturated ring group; A is an optionally substituted C-Caromatic group or an optionally substituted heteroaromatic group; X is a halogen atom or a sulfonic acid ester; and Yis bromine, iodine, chlorine or a carbanion ligand.

Process for production of aromatic compounds

The present invention relates to a fullerene derivative having a partial structure represented by the general formula (I): wherein Cto Care carbon atoms constituting a fullerene skeleton in which Cto Care independently bonded to an organic group having 1 to 50 carbon atoms, and Cis bonded to a substituted or unsubstituted alkyl group having 1 to 20 carbon atoms.

Fullerene derivatives and processes for producing the same

A metal complex contains at least one ligand, each having the form of a molecule of a fullerene derivative or an anion of the fullerene derivative, where the fullerene derivative, with a solubility in n-hexane of not lower that 0.1 mg/ml at 250&#xb0; C., includes a fullerene skeleton and three or more organic groups attached to the fullerene skeleton, where each of the organic groups is represented by the general formula (III):&#x2014;CH&#x2014;X(R)(R)(R) &#x2003;&#x2003;(III)where X represents an element belonging to the group 14 in the periodic table; and R, Rand Rmay be the same or different and each represents a hydrogen atom, hydrocarbon group, alkoxy group or amino group.

Fullerene derivatives and their metal complexes

A novel means for DNA compaction is provided. The object is accomplished by providing a fullerene derivative having 1 to 4 nitrogen-containing hydrophilic side chain(s) or its salt for DNA compaction. DNA compaction can be achieved effectively, and application to gene therapy is also expected.

A fullerene derivative, with a solubility in n-hexane of not lower that 0.1 mg/ml at 25&#xb0; C., includes a fullerene skeleton and three or more organic groups attached to the fullerene skeleton, where each of the organic groups is represented by the general formula (III):&#x2014;CH&#x2014;X (R)(R)(R)&#x2003;&#x2003;(III)where X represents an element belonging to the group 14 in the periodic table; and R, Rand Rmay be the same or different and each represents a hydrogen atom, hydrocarbon group, alkoxy group or amino group.

Growing community of inventors

Tokyo, Japan

Eiichi Nakamura